Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. Lichtiger S, et al. Among authors: binion dg. Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28. Aliment Pharmacol Ther. 2010. PMID: 20955442 Clinical Trial.
Polypharmacy and Crohn's disease.
Cross RK, Wilson KT, Binion DG. Cross RK, et al. Among authors: binion dg. Aliment Pharmacol Ther. 2005 May 15;21(10):1211-6. doi: 10.1111/j.1365-2036.2005.02429.x. Aliment Pharmacol Ther. 2005. PMID: 15882241
Durability of infliximab in Crohn's disease: a single-center experience.
Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Gonzaga JE, et al. Among authors: binion dg. Inflamm Bowel Dis. 2009 Dec;15(12):1837-43. doi: 10.1002/ibd.20974. Epub 2009 May 21. Inflamm Bowel Dis. 2009. PMID: 19462426
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, Chao J. Panaccione R, et al. Can J Gastroenterol. 2011 Aug;25(8):419-25. doi: 10.1155/2011/724813. Can J Gastroenterol. 2011. PMID: 21912766 Free PMC article. Clinical Trial.
222 results